Oversight & Investigations

WASHINGTON, D.C. – Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, delivered the following opening statement at today’s hearing titled Examining Biosecurity at the Intersection of AI and Biology.

Subcommittee Chairman Joyce’s opening statement as prepared for delivery:

“Good morning, and welcome to today’s hearing entitled “Examining Biosecurity at the Intersection of AI and Biology.

“The goal of today’s hearing is to examine a rapidly evolving threat landscape at the intersection of artificial intelligence (AI) and biotechnology. This convergence promises extraordinary breakthroughs for medicine, public health, and scientific discovery. It also introduces profound new risks to the safety and security of the American people.

“Our hearing today is about minimizing the risk of misuse to protect national security, while also maintaining public support of AI’s ability to assist with miraculous things—like finding life-saving cures for diseases.

“For decades, the United States has led the world in biotechnology. But what was once confined to specialized labs with highly trained scientists is now increasingly accessible far beyond traditional boundaries. Synthetic biology tools have become less expensive and more widely available. For example, a basic CRISPR gene-editing kit can be purchased online for under $300.

“Advanced AI systems—like large language models, or LLMs, and biological design tools capable of generating, troubleshooting, and optimizing biological designs—are moving faster than our existing oversight frameworks were built to anticipate.

“In recent years, studies have shown that cutting-edge AI models can walk users step-by-step through complex biological processes, including those relevant to developing or modifying dangerous pathogens. These tools can assist experts in breakthrough research, but they may also enable individuals with far less training to bypass barriers that once protected against accidental or intentional misuse. Some LLMs have even been shown to outperform PhD-level virologists on advanced troubleshooting tasks.

“There is also early evidence that AI systems can design entirely new biological entities. A recent study demonstrated that an AI model generated multiple synthetic viruses—some with capabilities that researchers previously believed were impossible.

“As a physician, I must acknowledge the extraordinary promise that AI-enabled biotechnology holds for patient care. AI is accelerating drug discovery, improving protein modeling, and enabling the development of therapies with unprecedented precision.

“But the same technological advancements can also raise the stakes for biosecurity. These risks are not theoretical. National security experts warn that adversarial nations—including China, North Korea, Iran, Russia, and others—may seek to exploit AI-enabled biological design tools for malicious purposes. We must take those warnings seriously.

“AI-enabled biotechnology presents issues that our current frameworks may not adequately account for. Existing government oversight systems—such as the Dual Use Research of Concern (DURC) policy—may not apply when an AI-designed organism is not identified as a Select Agent, not known to infect humans, or not developed with federal funds.

“The Trump administration has taken steps to keep up with such advancements, but the federal government must continue to carefully assess whether our current safeguards and reporting systems are adequate in an era of rapidly advancing AI technology.

“I want to thank our witnesses for being here today. Your expertise will help guide Congress as we confront this challenge.”

WASHINGTON, D.C. – Today, Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, led a hearing titled Examining Biosecurity at the Intersection of AI and Biology.

“As a physician, I must acknowledge the extraordinary promise that AI-enabled biotechnology holds for patient care. AI is accelerating drug discovery, improving protein modeling, and enabling the development of therapies with unprecedented precision,” said Chairman Joyce. “The Trump Administration has taken steps to keep up with such advancements, but the federal government must continue to carefully assess whether our current safeguards and reporting systems are adequate in an era of rapidly advancing AI technology.”

Watch the full hearing here

Below are key excerpts from today’s hearing:

Congressman Dan Crenshaw (TX-02): “We've talked a lot about how AI can be used for all sorts of scary things. What about the good parts? What about assisting industry leaders and researchers in identifying biosecurity risks? In other words, you know, how can we use AI for good?” Mr. McKnight: “Thank you for the question. This builds on the conversation we were having about select agent lists and then the new incredible diversity of threats. The same way the biodesign tools that we're talking about can create new proteins and give lessons on how to create new medicines, those same tools can be turned around. [...] They can be turned around to automate the process of interpreting a sample that you're looking at, and then the development roadmap that is funded through these programs is to use AI to go from sequence detection to what the function is.”

Congressman Russ Fulcher (ID-01): “In an attempt to try to close the door on this, President Trump had the executive order back in May. And looking at the gene synthesis, in the section of the President's EO of the gene synthesis section, can you say what specific parts of that order are actually going to stop these threats, or have the best chance of stopping these threats? Can they stop [those] threats if implemented? And, just a follow up, what else should we in Congress be doing about this?” Dr. Pannu: “Thank you for the question. Overall, I'm glad that you mentioned the executive order from May; I think that's an important initiative. There are a couple of things in that I would want to highlight: the gene synthesis provisions do call on Congress to proceed with a legislative effort to make gene synthesis screening mandatory across the U.S., that's something that Congress could advance. The other provisions on clearly defining what is dangerous gain of function research, those policies have yet to be released from the Office of Science and Technology Policy, so Congress could ask for an update as to those, and where they currently stand.”

Congresswoman Diana Harshbarger (TN-01): “Are there early warning indicators—whether they're digital, biological or supply chain—that could help identify AI-enabled biological misuse? Because you talked about that digital to physical barrier.” Mr. McKnight: “Yes, one of the key capabilities that we work on is when you take a sample with Biothreat Radar from an airport, or from a community, or from a threat location, you bring it, you do DNA sequencing with it. […] We have a set of tools that we are constantly developing with cutting edge machine learning AI to analyze that DNA to tell you what’s in it, what different types of pathogens, are there new things that you haven’t seen? And one of the very specific tools that we work on that was developed in conjunction with IARPA […] is a tool that actually looks and algorithmically scores to identify if something has been genetically engineered or not.”

WASHINGTON, D.C. – This week, the House Committee on Energy and Commerce is holding three Subcommittee Hearings. Read more below.

SUBCOMMITTEE HEARING: The Energy and Commerce Subcommittee on Communications and Technology is holding a hearing to discuss public safety communications in the United States.

• DATE: Tuesday, December 16, 2025
• TIME: 10:15 AM ET
• LOCATION: 2123 Rayburn House Office Building

SUBCOMMITTEE HEARING: The Energy and Commerce Subcommittee on Oversight and Investigations is holding a hearing to examine how AI and biotechnology advancements affect biosecurity and efforts to mitigate risks.

• DATE: Wednesday, December 17, 2025
• TIME: 10:15 AM ET
• LOCATION: 2123 Rayburn House Office Building

SUBCOMMITTEE HEARING: The Energy and Commerce Subcommittee on Environment is holding a hearing to discuss the current statutory and regulatory landscape for PFAS.

• DATE: Thursday, December 18, 2025
• TIME: 10:00 AM ET
• LOCATION: 2123 Rayburn House Office Building

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Environment, sent a letter to Steven S. Cliff, Ph.D., Executive Officer of the California Air Resources Board (CARB), demanding answers and documents that the Committee previously requested from CARB on California’s refusal to follow the law and implement the Clean Air Act as written by Congress. The Committee also requested transcribed interviews of six individuals if CARB fails to provide the previously requested information by December 5, 2025.    “The Committee’s August 11, 2025, letter requested information and documents from the California Air Resources Board (CARB) about California’s enforcement of state vehicle emission standards that disregard recent Congressional actions to disapprove waivers of federal preemption under the Clean Air Act,” said Chairmen Guthrie, Joyce, and Palmer. “Unfortunately, CARB’s responses to date have been woefully inadequate and do not satisfy the Committee’s important oversight interests in this matter.” Key excerpt from the letter: “Clean Air Act section 209(a) preempts states from adopting or attempting to enforce any emissions control standard for new motor vehicles or engines, or any condition precedent to the initial retail sale, registration or inspection of such vehicle or engine. Under section 209(b), the U.S. Environmental Protection Agency (EPA) may waive federal preemption, allowing California to establish state motor vehicle emission standards. However, Congress passed with bipartisan support, and President Trump signed, three resolutions under the Congressional Review Act (CRA) disapproving three waivers of preemption that the Biden-Harris Administration previously granted.” “Due to CARB’s failure to make a good faith effort to provide the requested information and documents, the Committee requests transcribed interviews with the following individuals if CARB fails to provide the requested information and documents by December 5, 2025: Lauren Sanchez, CARB Chair (from September 2025 to present); Liane Randolph, Former CARB Chair (from December 2021 to September 2025); Steven Cliff, CARB Executive Officer; Shannon Dilley, CARB Chief Counsel; Christopher Grundler, CARB Deputy Executive Officer – Mobile Sources & Incentives; and Robin Lang, Division Chief, CARB Emissions Certification & Compliance Division. “The Committee requests that these transcribed interviews be completed no later than December 12, 2025.” Background: Since President Trump signed the three Congressional Review Act resolutions into law, revoking California’s ability to set state emission standards that mandate the sale of EVs, the state cannot move forward with plans to ban the sale of gas-powered vehicles. The Committee’s August 11, 2025, request sought answers about California’s apparent enforcement of the preempted standards and requested copies of related documents, such as internal guidance CARB provided to its staff, communications with other states, internal correspondence between CARB officials and the Governor’s Office and the Office of Attorney General, and other internal documents concerning CARB’s response to the disapproval of the waivers of federal preemption. The requested information and documents will help the Committee understand how California is implementing the Clean Air Act in light of the federal preemption of state emission standards, and whether the waiver authority in Clean Air Act section 209(b) should be eliminated or otherwise modified. CLICK HERE to read the full letter .

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, sent a letter to the Centers for Medicare and Medicaid Services (CMS) requesting a briefing to better understand the Department of Health and Human Services’ (HHS) recent actions and ongoing work to enhance safety within the organ procurement and transplantation system. On Thursday, September 18, 2025, the Department of Health and Human Services (HHS) announced major efforts to improve safety, transparency, and efficiency within the organ procurement and transplantation system, including the decertification of an organ procurement organization (OPO) for the first time in U.S. history. According to the announcement , the decision was made “after an investigation uncovered years of unsafe practices, poor training, chronic underperformance, understaffing, and paperwork errors.” The Committee has a history of ensuring patient safety remains the highest priority in our organ procurement and transplantation system, as evident from the Committee’s work last Congress on organ transplantation and donation issues as well as its oversight this Congress. As a part of its ongoing investigation, the Committee requests that CMS respond to questions, including those related to the decertification of the OPO in South Florida and the prevalence of incidents similar to those outlined in the Health Resources and Services Administration’s (HRSA) investigative report, to ensure patient safety remains a top priority. Read the full letter HERE . “While the Committee applauds efforts taken by CMS to uphold the highest standards of care to which all OPOs are expected to adhere, HHS’s announcement decertifying the Life Alliance Organ Recovery Agency illustrates the urgency of this moment and why the subcommittee is not finished with our oversight of the organ transplant system,” said Chairmen Guthrie and Joyce. “It is our moral obligation as members of Congress to establish safeguards and prevent these harmful practices from persisting further, and we look forward to obtaining answers from the agency about the prevalence of these incidents, as well as how CMS plans to proceed with prioritizing patient safety first and foremost.” Background: During the 118th Congress, the Committee on Energy and Commerce led the passage of the Securing the U.S. Organ Procurement and Transplantation Network Act to both modernize the Organ Procurement and Transplantation Network (OPTN) and allow HRSA to institute a competitive contracting process to find the best contractors for various OPTN functions. This legislation was signed into law on September 22, 2023.  On March 20, 2024, the Committee launched an investigation into the organ procurement and transplantation system by sending a letter to United Network for Organ Sharing (UNOS) requesting information related to concerns surrounding data security and operability, patient safety and equity, and conflicts of interest.   On March 20, 2024, the Committee also sent a letter to HRSA requesting information related to implementation of the Securing the U.S. Organ Procurement and Transplantation Network Act as well as other concerns related to effective oversight and management.  On September 11, 2024, the Subcommittee on Oversight and Investigations held a hearing that focused on the implementation of reforms at the OPTN, including the need for stronger oversight and accountability as well as ongoing patient safety concerns.  During the hearing, questions were raised related to allegations of mismanagement and patient safety concerns after patients began exhibiting signs of increased neurologic function after being previously deemed suitable as an organ donation candidate. Several of these allegations, particularly those related to patient safety, were later substantiated through the findings contained in HRSA’s March 2025 report.  On March 24, 2025, HRSA’s Division of Transplantation issued a report that summarized the findings of its investigation into KYDA, the OPO now known as Network for Hope, which serves Kentucky and parts of Ohio, West Virginia, and Indiana.   HRSA’s investigation examined an “index case” and an additional 351 unique cases of authorized, not recovered (ANR) patients. This means that the patients were considered for donation after circulatory death recovery, but no organs were transplanted. The report showed that nearly 30 percent of the cases “had concerning features.” The concerning features included problems with patient-family interactions, medical assessments and team interactions, recognition of high neurologic function, and recognition and documentation of drugs in records.  On May 28, 2025, HRSA issued a corrective action plan to the OPTN, which directed the OTPN to take specific actions within a specified period of time, including developing a 12-month OPTN monitoring plan for KYDA to address concerns identified. The corrective action plan also requires the OPTN to propose policies for public comment to improve safeguards for potential donation after circulatory death (DCD) patients in the organ procurement process and increase information shared with patient families regarding DCD organ procurement.  On July 22, 2025, the House Committee on Energy and Commerce’s Subcommittee on Oversight and Investigations held a hearing examining concerning practices within our nation’s organ procurement and transplant system that were identified by HRSA’s investigation.  On September 12, 2025, the Committee sent a bipartisan letter to HRSA requesting a briefing on its ongoing oversight of patient safety in our nation’s organ procurement and transplant system. ###

WASHINGTON, D.C. – Yesterday, Congressman John Joyce, M.D. (PA-13), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Environment, sent a letter to Gene Dodaro, the Comptroller General of the Government Accountability Office (GAO), requesting an assessment of available or emerging technologies and materials that could be used to supplement critical minerals in semiconductors. “Critical minerals such as lithium, cobalt, and rare earth elements are essential for technologies used in many sectors of the economy, including energy, transportation, national defense, health care, and consumer electronics,” said Chairmen Joyce and Palmer . “These minerals are vulnerable to supply-chain disruptions for several reasons, including U.S. reliance on foreign sources, as well as the rapid growth in demand for critical minerals in the U.S. and abroad.” CLICK HERE to read the full letter. The letter asks the GAO to examine: The status of domestic technologies and supplemental materials, such as critical minerals found in mine waste, tailings, or reclaimed from end-of-life batteries and electronic waste, that can serve as substitutes for foreign-sourced critical minerals from non-allied nations needed for semiconductors and energy grid or power electronics, including impacts on material and product performance. Key technological challenges to the development or adoption of these domestic supplemental and materials to advance the diversification of U.S. critical mineral sources. BACKGROUND: In May, the Subcommittee on Oversight and Investigations held a hearing on ways to enhance our critical mineral supply chains. Energy and Commerce Committee Republicans are committed to strengthening our critical mineral supply chains and finding solutions to reduce our reliance on foreign sources, particularly when it comes to foreign adversaries like China. The Trump Administration has also worked hard to bolster these supply chains. Critical minerals are essential to American technologies and industries, and finding innovative domestic solutions that can contribute to our independence from non-allied nations is essential as we work to onshore American innovation and strengthen our national security. ###